TID Research Updates
Dear JDRF Supporter,
I wanted to share an update to tell you about some great work underway at JDRF. In the past months, with your support, we’ve made strides toward our goal to do the greatest good for the most people in the shortest amount of time until we find a cure.
In January, we announced the JDRF T1D Fund, a nonprofit fund that invests in the most promising companies pursuing type 1 diabetes (T1D) drugs, devices, diagnostics and vaccines to help bring them to market, and to you, faster. So far, the T1D Fund has supported six innovative programs in artificial pancreas technologies, glucose control, prevention, immunotherapy and beta cell replacement. We believed that this new model could attract new private investments in T1D, and it has.
I’m also pleased to report that as of the end of June, the Fund raised more than $50 million, thanks to the contributions of 27 major donors, in addition to JDRF’s commitment of $32 million. We are well on our way to the $80 million in assets we hope to have in the Fund after two years.
You can read about the T1D Fund’s progress in a recent article published by The New York Times, which explains the unique approach JDRF undertook and highlights the stellar leadership of Sean Doherty — the T1D Fund’s chair and a longtime volunteer leader — who has been critical to this effort.
Of course, the Fund is one of our many initiatives aimed at fulfilling our mission. JDRF has funded more than $100 million for T1D research in fiscal year 2016, and our successful advocacy work has resulted in the United States and other governments around the world directing nearly $3 billion toward T1D research.Because of our work together, there is more money being spent today to find a cure for T1D than at any other time in history.
To keep this up, two weeks ago we held a very successful JDRF 2017 Children’s Congress on Capitol Hill, as part of our effort to urge Congress to renew the Special Diabetes Program (SDP) at the current funding level of $150 million per year. Because of the research that has been funded by this National Institutes of Health (NIH) program, there has been significant progress toward developing better treatments, advances in prevention studies and research to achieve the ultimate objective: a cure. We are pressing Congress to renew SDP for another three years so researchers can continue their progress. The good news is members of both political parties expressed support for extending SDP. As we advocate for more funding, we are also fighting so that the T1D Community has insurance coverage to afford the advancements that come from research. Our “Coverage 2 Control” campaign is making this case and gaining support.
These are just a few updates to highlight the incredible progress you have made possible. If you would like to learn more, please visit our website or feel free to contact us. I am ever grateful for your support. Together, we will achieve our vision of a world without T1D.
All the best,
Derek K. Rapp
President & Chief Executive Officer
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D.